JP5764064B2 - 抗糖尿病薬として有用な新規な環状ベンゾイミダゾール誘導体 - Google Patents
抗糖尿病薬として有用な新規な環状ベンゾイミダゾール誘導体 Download PDFInfo
- Publication number
- JP5764064B2 JP5764064B2 JP2011529149A JP2011529149A JP5764064B2 JP 5764064 B2 JP5764064 B2 JP 5764064B2 JP 2011529149 A JP2011529149 A JP 2011529149A JP 2011529149 A JP2011529149 A JP 2011529149A JP 5764064 B2 JP5764064 B2 JP 5764064B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- substituted
- unsubstituted
- cycloalkyl
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- TVOAXRDXTGCPBB-UHFFFAOYSA-N Brc(cc1)ncc1-c1ccccc1 Chemical compound Brc(cc1)ncc1-c1ccccc1 TVOAXRDXTGCPBB-UHFFFAOYSA-N 0.000 description 1
- FSTVWMHOSNIRRJ-UHFFFAOYSA-N CC(c(cc1)ccc1-c(cc(c([nH]1)c2)nc1Oc1ccc(C)c(C(O)=O)c1)c2Cl)O Chemical compound CC(c(cc1)ccc1-c(cc(c([nH]1)c2)nc1Oc1ccc(C)c(C(O)=O)c1)c2Cl)O FSTVWMHOSNIRRJ-UHFFFAOYSA-N 0.000 description 1
- XOYOXHVNYCDDLL-UHFFFAOYSA-N CN(C)c(c(F)c1)ccc1Br Chemical compound CN(C)c(c(F)c1)ccc1Br XOYOXHVNYCDDLL-UHFFFAOYSA-N 0.000 description 1
- PHOKOCSTFFPSBN-UHFFFAOYSA-N COC(C[n]1nnc(-c2cc(O)ccc2)n1)=O Chemical compound COC(C[n]1nnc(-c2cc(O)ccc2)n1)=O PHOKOCSTFFPSBN-UHFFFAOYSA-N 0.000 description 1
- KOBQALGVZVXCSK-UHFFFAOYSA-N CS(c1nc(c(F)c(c(F)c2)I)c2[n]1Cc(cc1)ccc1-c1ccccc1)(=O)=O Chemical compound CS(c1nc(c(F)c(c(F)c2)I)c2[n]1Cc(cc1)ccc1-c1ccccc1)(=O)=O KOBQALGVZVXCSK-UHFFFAOYSA-N 0.000 description 1
- YFHCTVCJFUZFTO-UHFFFAOYSA-N Cc(c(C(O)=O)c1)ccc1Oc([nH]c1c2)nc1cc(-c1ccc(C3(CO)CC3)cc1)c2Cl Chemical compound Cc(c(C(O)=O)c1)ccc1Oc([nH]c1c2)nc1cc(-c1ccc(C3(CO)CC3)cc1)c2Cl YFHCTVCJFUZFTO-UHFFFAOYSA-N 0.000 description 1
- WFERJTBSKOXRPN-UHFFFAOYSA-N Cc(c(C(O)=O)c1)ccc1Oc([nH]c1c2)nc1cc(C#Cc1ccccc1F)c2Cl Chemical compound Cc(c(C(O)=O)c1)ccc1Oc([nH]c1c2)nc1cc(C#Cc1ccccc1F)c2Cl WFERJTBSKOXRPN-UHFFFAOYSA-N 0.000 description 1
- WSCICVKOCLOHGM-UHFFFAOYSA-N Cc1c(C)c(C(OC)=O)cc(O)c1 Chemical compound Cc1c(C)c(C(OC)=O)cc(O)c1 WSCICVKOCLOHGM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/28—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19433708P | 2008-09-26 | 2008-09-26 | |
| US61/194,337 | 2008-09-26 | ||
| PCT/US2009/057686 WO2010036613A1 (en) | 2008-09-26 | 2009-09-21 | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012503661A JP2012503661A (ja) | 2012-02-09 |
| JP2012503661A5 JP2012503661A5 (https=) | 2012-09-27 |
| JP5764064B2 true JP5764064B2 (ja) | 2015-08-12 |
Family
ID=41395799
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011529149A Active JP5764064B2 (ja) | 2008-09-26 | 2009-09-21 | 抗糖尿病薬として有用な新規な環状ベンゾイミダゾール誘導体 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8394969B2 (https=) |
| EP (1) | EP3924343A1 (https=) |
| JP (1) | JP5764064B2 (https=) |
| CN (1) | CN102361857B (https=) |
| AR (1) | AR073677A1 (https=) |
| AU (1) | AU2009296820B2 (https=) |
| CA (1) | CA2737694C (https=) |
| MX (1) | MX2011003239A (https=) |
| TW (1) | TWI393709B (https=) |
| WO (1) | WO2010036613A1 (https=) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010047982A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| WO2010051176A1 (en) | 2008-10-29 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| JP5557845B2 (ja) | 2008-10-31 | 2014-07-23 | メルク・シャープ・アンド・ドーム・コーポレーション | 糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体 |
| WO2011103018A1 (en) | 2010-02-18 | 2011-08-25 | High Point Pharmaceuticals, Llc | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof |
| US8759535B2 (en) | 2010-02-18 | 2014-06-24 | High Point Pharmaceuticals, Llc | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof |
| US8895596B2 (en) | 2010-02-25 | 2014-11-25 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
| US8344137B2 (en) * | 2010-04-14 | 2013-01-01 | Hoffman-La Roche Inc. | 3,3-dimethyl tetrahydroquinoline derivatives |
| WO2012033149A1 (ja) | 2010-09-10 | 2012-03-15 | 塩野義製薬株式会社 | Ａｍｐｋ活性化作用を有するヘテロ環縮合イミダゾール誘導体 |
| WO2012047772A2 (en) * | 2010-10-07 | 2012-04-12 | Schering Corporation | Imidazole derivatives |
| WO2012064569A1 (en) * | 2010-11-08 | 2012-05-18 | Merck Sharp & Dohme Corp. | Imidazole derivatives |
| FR2968213B1 (fr) | 2010-12-03 | 2014-03-21 | Oreal | Utilisation d'une association amincissante |
| AR084174A1 (es) | 2010-12-21 | 2013-04-24 | Lilly Co Eli | Compuestos de imidazol-2-benzamida utiles para el tratamiento de osteoartritis y una composicion farmaceutica |
| BR112013021236B1 (pt) | 2011-02-25 | 2021-05-25 | Merck Sharp & Dohme Corp | composto derivado de benzimidazol, e, composição |
| WO2012162635A1 (en) * | 2011-05-26 | 2012-11-29 | Sunovion Pharmaceuticals Inc. | Metabotropic glutamate receptors 5 modulators and methods of use thereof |
| EP2733141B1 (en) | 2011-07-15 | 2019-01-09 | Shionogi & Co., Ltd. | Azabenzimidazole derivative having ampk-activating activity |
| TWI449702B (zh) * | 2012-07-11 | 2014-08-21 | Merck Sharp & Dohme | 作為抗糖尿病劑之新穎環氮雜苯并咪唑衍生物 |
| US9527875B2 (en) | 2012-08-02 | 2016-12-27 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| WO2014031465A1 (en) | 2012-08-22 | 2014-02-27 | Merck Sharp & Dohme Corp. | Novel azabenzimidazole tetrahydropyran derivatives |
| US9540364B2 (en) | 2012-08-22 | 2017-01-10 | Merck Sharp & Dohme Corp. | Benzimidazole tetrahydrofuran derivatives |
| WO2014031468A1 (en) | 2012-08-22 | 2014-02-27 | Merck Sharp & Dohme Corp. | Novel benzimidazole hexahydrofuro[3,2-b]furan derivatives |
| WO2014031517A1 (en) | 2012-08-22 | 2014-02-27 | Merck Sharp & Dohme Corp. | Novel azabenzimidazole tetrahydrofuran derivatives |
| US9527839B2 (en) | 2012-08-22 | 2016-12-27 | Merck Sharp & Dohme Corp. | Benzimidazole tetrahydropyran derivatives |
| RU2015109706A (ru) * | 2012-08-22 | 2016-10-10 | Мерк Шарп И Доум Корп. | Новые производные азабензимидазол гексагидрофуро[3, 2-в]фурана |
| EP2963013A4 (en) | 2013-02-27 | 2016-09-14 | Shionogi & Co | INDOLE AND AZAINDOLE DERIVATIVES HAVING AMPK ACTIVATION ACTIVITY EACH |
| WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| ES2747973T3 (es) | 2013-11-15 | 2020-03-12 | Merck Sharp & Dohme | Compuestos tricíclicos antidiabéticos |
| WO2015089809A1 (en) | 2013-12-19 | 2015-06-25 | Merck Sharp & Dohme Corp. | Antidiabetic substituted heteroaryl compounds |
| US10143703B2 (en) | 2014-01-02 | 2018-12-04 | Massachusetts Eye And Ear Infirmary | Treating ocular neovascularization |
| US10669296B2 (en) | 2014-01-10 | 2020-06-02 | Rgenix, Inc. | LXR agonists and uses thereof |
| US9980948B2 (en) | 2014-08-27 | 2018-05-29 | Shionogi & Co., Ltd. | Azaindole derivative having AMPK-activating activity |
| MX2017005158A (es) * | 2014-10-28 | 2017-07-27 | Shionogi & Co | Derivado heterociclico que tiene actividad de activacion de proteina cinasa activada por adenosina monofostato (ampk). |
| WO2016089648A1 (en) | 2014-12-01 | 2016-06-09 | Vtv Therapeutics Llc | Bach 1 inhibitors in combination with nrf2 activators and pharmaceutical compositions thereof |
| CN104961703A (zh) * | 2015-07-14 | 2015-10-07 | 佛山市赛维斯医药科技有限公司 | 一类苯并异恶唑类11β-HSD1抑制剂、制备方法及其用途 |
| CN104961702A (zh) * | 2015-07-14 | 2015-10-07 | 佛山市赛维斯医药科技有限公司 | 苯并异恶唑类11β-HSD1抑制剂、制备方法及其用途 |
| CN105596333A (zh) * | 2016-02-02 | 2016-05-25 | 白强 | 一种防治糖尿病及其并发症的药物组合物及其应用 |
| JPWO2017146186A1 (ja) | 2016-02-26 | 2018-12-20 | 塩野義製薬株式会社 | Ａｍｐｋ活性化作用を有する５−フェニルアザインドール誘導体 |
| CN109476661A (zh) | 2016-05-20 | 2019-03-15 | 盐野义制药株式会社 | 具有ampk活化作用的5-取代苯并咪唑及5-取代氮杂苯并咪唑衍生物 |
| CA3032830A1 (en) * | 2016-08-19 | 2018-02-22 | Rigel Pharmaceuticals, Inc. | Benzimidazole direct ampk activators |
| CN118206529A (zh) | 2017-09-04 | 2024-06-18 | C4医药公司 | 二氢苯并咪唑酮 |
| EP3713575A4 (en) | 2017-11-21 | 2021-08-25 | Rgenix, Inc. | POLYMORPHS AND THEIR USES |
| CN108503632B (zh) * | 2018-06-26 | 2020-07-28 | 北京圣永制药有限公司 | 一种吲哚类衍生物及其在糖尿病中的应用 |
| WO2020181232A1 (en) | 2019-03-06 | 2020-09-10 | C4 Therapeutics, Inc. | Heterocyclic compounds for medical treatment |
| CA3137224A1 (en) | 2019-04-19 | 2020-10-22 | Sorbonne Universite | P16ink4a inhibitor for preventing or treating huntington's disease |
| HUE067466T2 (hu) | 2019-12-13 | 2024-10-28 | Inspirna Inc | Fémsók és alkalmazásuk |
| WO2021160109A1 (zh) * | 2020-02-13 | 2021-08-19 | 劲方医药科技(上海)有限公司 | 二氢萘啶酮类化合物，其制法与医药上的用途 |
| IL295825A (en) | 2020-02-28 | 2022-10-01 | Kallyope Inc | gpr40 agonists |
| AR121842A1 (es) * | 2020-04-15 | 2022-07-13 | Ache Laboratorios Farmaceuticos Sa | Compuesto de benzimidazol para el tratamiento de trastornos metabólicos |
| WO2021236617A1 (en) | 2020-05-19 | 2021-11-25 | Kallyope, Inc. | Ampk activators |
| CA3183575A1 (en) | 2020-06-26 | 2021-12-30 | Iyassu Sebhat | Ampk activators |
| JP2024540522A (ja) | 2021-11-19 | 2024-10-31 | ザ・ブロード・インスティテュート・インコーポレイテッド | キナーゼを標的結合部分で標識するための二官能性キメラ分子及びその使用方法 |
| TW202329944A (zh) * | 2021-11-23 | 2023-08-01 | 美商克力歐普股份有限公司 | Ampk活化劑 |
| CN117050043A (zh) * | 2022-05-13 | 2023-11-14 | 中国海洋大学 | 一种3-苯基二苯并呋喃类化合物及其制备方法和用途 |
| CN117243950A (zh) * | 2023-10-31 | 2023-12-19 | 首都医科大学附属北京朝阳医院 | Mk-3903在制备预防和/或治疗缺血性心脏病的药物中的应用 |
| WO2025101276A1 (en) * | 2023-11-06 | 2025-05-15 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Compositions and methods for making and using immune cells |
| CN118702677A (zh) * | 2024-06-26 | 2024-09-27 | 沈阳药科大学 | 一种ampk激动剂及其衍生物与其制备方法和用途 |
Family Cites Families (100)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2472574A1 (fr) * | 1979-12-24 | 1981-07-03 | Ici Pharma | Derives de cephalosporine et composition pharmaceutique les contenant |
| JPS57151944A (en) | 1981-03-16 | 1982-09-20 | Fuji Photo Film Co Ltd | Color photosensitive silver halide material |
| JPS58193541A (ja) | 1982-05-07 | 1983-11-11 | Konishiroku Photo Ind Co Ltd | 熱現像画像記録材料 |
| JPH0245181B2 (ja) | 1983-03-16 | 1990-10-08 | Fuji Photo Film Co Ltd | Netsugenzokaraakankozairyo |
| GB8313322D0 (en) | 1983-05-14 | 1983-06-22 | Ciba Geigy Ag | Heterocyclic-(cyclo)aliphatic carboxylic acids |
| GB8313320D0 (en) | 1983-05-14 | 1983-06-22 | Ciba Geigy Ag | Coating compositions |
| GB8313321D0 (en) | 1983-05-14 | 1983-06-22 | Ciba Geigy Ag | Preparation of mercaptan substituted carboxylic acids |
| GB8412065D0 (en) | 1984-05-11 | 1984-06-20 | Ciba Geigy Ag | Preparation of carboxylic acid derivatives |
| GB8412064D0 (en) | 1984-05-11 | 1984-06-20 | Ciba Geigy Ag | Compositions containing heterocyclic corrosion inhibitors |
| GB8412063D0 (en) | 1984-05-11 | 1984-06-20 | Ciba Geigy Ag | Compositions containing heterocyclic corrosion inhibitors |
| GB8525452D0 (en) * | 1985-10-16 | 1985-11-20 | Fisons Plc | Biologically active nitrogen heterocycles |
| EG17993A (en) * | 1986-02-03 | 1991-08-30 | Janssen Pharmaceutica Nv | Anti-histaminic compositions containing n-heterocyclyl-4-piperidinanines |
| JPH01501473A (ja) * | 1986-09-27 | 1989-05-25 | フアイソンズ・ピーエルシー | 化合物 |
| US4851423A (en) | 1986-12-10 | 1989-07-25 | Schering Corporation | Pharmaceutically active compounds |
| CA1317939C (en) * | 1987-07-01 | 1993-05-18 | Janssen Pharmaceutica Naamloze Vennootschap | ¬(bicyclic heterocyclyl)methyl and -hetero| substituted hexahydro-1h-azepines and pyrrolidines |
| US5409930A (en) | 1991-05-10 | 1995-04-25 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| PT100905A (pt) | 1991-09-30 | 1994-02-28 | Eisai Co Ltd | Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem |
| US5559127A (en) | 1992-10-14 | 1996-09-24 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
| JPH06298731A (ja) | 1993-04-13 | 1994-10-25 | Fuji Photo Film Co Ltd | 複素環化合物の製造方法 |
| DE4326151A1 (de) | 1993-08-04 | 1995-02-09 | Hoechst Ag | Aromatische Verbindungen und ihre Verwendung in flüssigkristallinen Mischungen |
| CA2134192A1 (en) | 1993-11-12 | 1995-05-13 | Michael L. Denney | 5, 6-bicyclic glycoprotein iib/iiia antagonists |
| WO1995029897A1 (en) | 1994-04-29 | 1995-11-09 | G.D. Searle & Co. | METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS |
| AU690302B2 (en) * | 1994-06-30 | 1998-04-23 | Dade Behring Inc. | Bioactive porous partition members |
| JPH09227854A (ja) | 1996-02-26 | 1997-09-02 | Toyo Ink Mfg Co Ltd | 感エネルギー線酸発生剤、感エネルギー線酸発生剤組成物、硬化性組成物およびその硬化物 |
| EP0922028A1 (en) | 1996-08-26 | 1999-06-16 | Genetics Institute, Inc. | Inhibitors of phospholipase enzymes |
| US6054587A (en) | 1997-03-07 | 2000-04-25 | Metabasis Therapeutics, Inc. | Indole and azaindole inhibitors of fructose-1,6-bisphosphatase |
| DE69819311T2 (de) | 1997-03-07 | 2004-07-29 | Metabasis Therapeutics Inc., San Diego | Neue benzimidazol inhibitoren der fructose-1,6-bisphosphatase |
| AU6452098A (en) | 1997-03-07 | 1998-09-22 | Metabasis Therapeutics, Inc. | Novel purine inhibitors of fructose-1,6-bisphosphatase |
| DE69816992T2 (de) | 1997-06-10 | 2004-07-22 | Glaxo Group Ltd., Greenford | Benzimidazolderivate |
| EP1062216A1 (en) | 1998-02-25 | 2000-12-27 | Genetics Institute, Inc. | Inhibitors of phospholipase a2 |
| WO1999045016A2 (en) | 1998-03-06 | 1999-09-10 | Metabasis Therapeutics, Inc. | Novel prodrugs for phosphorus-containing compounds |
| US6312662B1 (en) * | 1998-03-06 | 2001-11-06 | Metabasis Therapeutics, Inc. | Prodrugs phosphorus-containing compounds |
| AU758789B2 (en) | 1998-07-15 | 2003-03-27 | Teijin Limited | Thiobenzimidazole derivatives |
| ATE246197T1 (de) * | 1998-09-09 | 2003-08-15 | Metabasis Therapeutics Inc | Neue heteroaromatische fructose 1,6- bisphosphatase inhibitoren |
| SE9900211D0 (sv) * | 1999-01-25 | 1999-01-25 | Pharmacia & Upjohn Ab | New compounds |
| HUP0200260A3 (en) | 1999-03-05 | 2002-11-28 | Metabasis Therapeutics Inc San | Novel phosphorus-containing prodrugs, their preparation and their use |
| IL147308A0 (en) * | 1999-06-30 | 2002-08-14 | Tularik Inc | Compounds for the modulation of pparγ activity and pharmaceutical compositions containing the same |
| EP1222187B1 (en) | 1999-10-06 | 2004-09-22 | Boehringer Ingelheim Pharmaceuticals Inc. | Heterocyclic compounds useful as inhibitors of tyrosine kinases |
| CN100415723C (zh) | 2000-01-17 | 2008-09-03 | 帝人株式会社 | 苯并咪唑衍生物 |
| WO2001053272A1 (en) | 2000-01-17 | 2001-07-26 | Teijin Limited | Human chymase inhibitors |
| US6844295B2 (en) * | 2000-07-04 | 2005-01-18 | Ube Industries, Ltd. | Benzoxazole compound, process for producing the same, and herbicide |
| JP4734705B2 (ja) | 2000-10-31 | 2011-07-27 | 三菱化学株式会社 | リチウム二次電池用正極材料、リチウム二次電池用正極及びリチウム二次電池 |
| WO2002040019A1 (en) | 2000-11-15 | 2002-05-23 | Banyu Pharmaceutical Co.,Ltd. | Benzimidazole derivatives |
| US7030150B2 (en) | 2001-05-11 | 2006-04-18 | Trimeris, Inc. | Benzimidazole compounds and antiviral uses thereof |
| EP1419785A4 (en) | 2001-08-24 | 2005-07-06 | Teijin Ltd | MEDICAMENTS CONTAINING A CHYMASE INHIBITOR AND ACE INHIBITOR AS ACTIVE INGREDIENTS |
| FR2829765A1 (fr) | 2001-09-14 | 2003-03-21 | Lipha | Derives imidazolylalkoxylarylalcanoiques leurs applications en therapeutique |
| SE0104331D0 (sv) * | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Novel compounds |
| US20050113283A1 (en) * | 2002-01-18 | 2005-05-26 | David Solow-Cordero | Methods of treating conditions associated with an EDG-4 receptor |
| EP1513522A2 (en) | 2002-01-18 | 2005-03-16 | Sri International | Methods of treating conditions associated with an edg receptor |
| JP2005289816A (ja) * | 2002-05-14 | 2005-10-20 | Banyu Pharmaceut Co Ltd | ベンズイミダゾール誘導体 |
| JP2004067629A (ja) | 2002-08-09 | 2004-03-04 | Yamanouchi Pharmaceut Co Ltd | ミトコンドリア機能活性化剤及び新規なベンゾイミダゾール誘導体 |
| WO2004035740A2 (en) | 2002-10-15 | 2004-04-29 | Synta Pharmaceuticals Corp. | Aromatic bicyclic heterocyles to modulate 1l - 12 production |
| FR2846656B1 (fr) * | 2002-11-05 | 2004-12-24 | Servier Lab | Nouveaux derives d'imidazopyridine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US20040166137A1 (en) | 2002-11-08 | 2004-08-26 | Lackey John William | Hetero-substituted benzimidazole compounds and antiviral uses thereof |
| JP2006518738A (ja) | 2003-02-12 | 2006-08-17 | トランス テック ファーマ，インコーポレイテッド | 治療薬としての置換アゾール誘導体 |
| US7531553B2 (en) | 2003-03-21 | 2009-05-12 | Amgen Inc. | Heterocyclic compounds and methods of use |
| AU2004238240A1 (en) * | 2003-05-09 | 2004-11-25 | Merck & Co., Inc. | Benzimidazoles, compositions containing such compounds and methods of use |
| US7119205B2 (en) * | 2003-05-16 | 2006-10-10 | Abbott Laboratories | Thienopyridones as AMPK activators for the treatment of diabetes and obesity |
| EP1646614A4 (en) | 2003-07-01 | 2008-09-10 | Merck & Co Inc | OPHTHALMIC COMPOSITIONS FOR THE TREATMENT OF OCCULAR HYPERTONIA |
| JP4836788B2 (ja) | 2003-07-23 | 2011-12-14 | エグゼリクシス， インコーポレイテッド | 未分化リンパ腫キナーゼ変調因子及びその使用法 |
| US7008953B2 (en) * | 2003-07-30 | 2006-03-07 | Agouron Pharmaceuticals, Inc. | 3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation |
| CN1829713A (zh) * | 2003-07-30 | 2006-09-06 | 辉瑞大药厂 | 3,5二取代的吲唑化合物、药物组合物和介导或抑制细胞增殖的方法 |
| WO2005020892A2 (en) | 2003-08-08 | 2005-03-10 | Mitochroma Research, Inc. | Pharmaceutical compositions and methods for metabolic modulation |
| US20050148643A1 (en) * | 2003-08-19 | 2005-07-07 | Agouron Pharmaceuticals, Inc. | Carbamate compositions and methods fo rmodulating the activity of the CHK1 enzyme |
| US20070032466A1 (en) | 2003-08-22 | 2007-02-08 | Teijin Pharma Limited | Drug containing chymase inhibitor as the active ingredient |
| US20050164300A1 (en) | 2003-09-15 | 2005-07-28 | Plexxikon, Inc. | Molecular scaffolds for kinase ligand development |
| US20050107374A1 (en) | 2003-10-21 | 2005-05-19 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| CA2543707A1 (en) * | 2003-10-31 | 2005-05-19 | Takeda Pharmaceutical Company Limited | Nitrogen-containing fused heterocyclic compounds |
| US8969372B2 (en) | 2003-11-14 | 2015-03-03 | Aptose Boisciences Inc. | Aryl imidazoles and their use as anti-cancer agents |
| JP4898458B2 (ja) * | 2004-02-12 | 2012-03-14 | トランス テック ファーマ，インコーポレイテッド | 置換アゾール誘導体、組成物及び使用方法 |
| US20050250820A1 (en) * | 2004-03-08 | 2005-11-10 | Amgen Inc. | Therapeutic modulation of PPARgamma activity |
| US7097961B2 (en) * | 2004-05-17 | 2006-08-29 | Agfa Gevaert | Stabilizers for use in substantially light-insensitive thermographic recording materials |
| JP2008501714A (ja) * | 2004-06-04 | 2008-01-24 | 武田薬品工業株式会社 | ジペプチジルペプチダーゼインヒビター |
| WO2005121132A1 (ja) | 2004-06-11 | 2005-12-22 | Shionogi & Co., Ltd. | 抗ｈｃｖ作用を有する縮合ヘテロ環化合物 |
| US20070054916A1 (en) * | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| JP2008518988A (ja) | 2004-11-02 | 2008-06-05 | ディーエスエム アイピー アセッツ ビー．ブイ． | Ｕｖ−日焼け止め調製物のための添加剤 |
| WO2006053342A2 (en) | 2004-11-12 | 2006-05-18 | Osi Pharmaceuticals, Inc. | Integrin antagonists useful as anticancer agents |
| US7429608B2 (en) * | 2005-01-20 | 2008-09-30 | Amgen Inc. | Benzo[d]imidazol analogs as vanilloid receptor ligands and their use in treatments |
| WO2006094209A2 (en) | 2005-03-03 | 2006-09-08 | Sirtris Pharmaceuticals, Inc. | N-benzimidazolylalkyl-substituted amide sirtuin modulators |
| ES2400287T3 (es) | 2005-03-14 | 2013-04-08 | High Point Pharmaceuticals, Llc | Derivados de benzazol, composiciones y procedimientos de uso como inhibidores de beta-secretasa |
| TWI370820B (en) | 2005-04-27 | 2012-08-21 | Takeda Pharmaceutical | Fused heterocyclic compounds |
| JP2009500351A (ja) * | 2005-07-04 | 2009-01-08 | ドクター レディズ ラボラトリーズ リミテッド | Ａｍｐｋアクチベータとしてのチアゾール誘導体 |
| JPWO2007007463A1 (ja) | 2005-07-11 | 2009-01-29 | 出光興産株式会社 | 電子吸引性置換基を有する含窒素複素環誘導体及びそれを用いた有機エレクトロルミネッセンス素子 |
| JPWO2007007464A1 (ja) | 2005-07-11 | 2009-01-29 | 出光興産株式会社 | 含窒素複素環誘導体及びそれを用いた有機エレクトロルミネッセンス素子 |
| JP2007039406A (ja) | 2005-08-05 | 2007-02-15 | Idemitsu Kosan Co Ltd | 含窒素複素環誘導体及びそれを用いた有機エレクトロルミネッセンス素子 |
| ES2432361T3 (es) * | 2005-12-02 | 2013-12-03 | Bayer Healthcare, Llc | Derivados de pirrolotriazina útiles para el tratamiento de cáncer por inhibición de cinasa Aurora |
| JP2007153778A (ja) | 2005-12-02 | 2007-06-21 | Idemitsu Kosan Co Ltd | 含窒素複素環誘導体及びそれを用いた有機エレクトロルミネッセンス素子 |
| WO2007084390A2 (en) | 2006-01-13 | 2007-07-26 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| CN102633783A (zh) | 2006-02-10 | 2012-08-15 | 转化技术制药公司 | 作为Aurora激酶抑制剂的苯并唑系衍生物、组合物和使用方法 |
| MX2008010187A (es) | 2006-02-10 | 2008-10-31 | Summit Corp Plc | Tratamiento de distrofia muscular de duchenne. |
| FR2903695B1 (fr) * | 2006-07-13 | 2008-10-24 | Merck Sante Soc Par Actions Si | Utilisation de derives d'imidazole activateurs de l'ampk, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| CA2657787A1 (en) | 2006-07-14 | 2008-01-17 | Merck And Co., Inc. | 2-substituted proline bis-amide orexin receptor antagonists |
| EP1878724A1 (en) | 2006-07-15 | 2008-01-16 | sanofi-aventis | A regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles |
| US8486370B2 (en) * | 2006-09-08 | 2013-07-16 | The Regents Of The University Of California | Heterocyclic ligands for integrin imaging and therapy |
| US20100056515A1 (en) * | 2006-10-25 | 2010-03-04 | Kazuyoshi Aso | Benzimidazole compounds |
| JP5294872B2 (ja) | 2006-11-20 | 2013-09-18 | 出光興産株式会社 | 有機エレクトロルミネッセンス素子 |
| CN101674827A (zh) * | 2007-03-02 | 2010-03-17 | 先灵公司 | 苯并咪唑衍生物及其使用方法 |
| JP2010535708A (ja) | 2007-08-03 | 2010-11-25 | ビオマリン アイジーエー リミテッド | デュシェンヌ型筋ジストロフィーの治療のための薬物併用 |
| MX2010008376A (es) | 2008-02-04 | 2011-02-22 | Mercury Therapeutics Inc | Moduladores ampk. |
| UY32138A (es) * | 2008-09-25 | 2010-04-30 | Boehringer Ingelheim Int | Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables |
-
2009
- 2009-09-21 CN CN200980147275.5A patent/CN102361857B/zh active Active
- 2009-09-21 AU AU2009296820A patent/AU2009296820B2/en active Active
- 2009-09-21 WO PCT/US2009/057686 patent/WO2010036613A1/en not_active Ceased
- 2009-09-21 CA CA2737694A patent/CA2737694C/en active Active
- 2009-09-21 MX MX2011003239A patent/MX2011003239A/es active IP Right Grant
- 2009-09-21 JP JP2011529149A patent/JP5764064B2/ja active Active
- 2009-09-21 EP EP09792782.6A patent/EP3924343A1/en not_active Withdrawn
- 2009-09-21 US US12/563,782 patent/US8394969B2/en active Active
- 2009-09-24 TW TW098132353A patent/TWI393709B/zh not_active IP Right Cessation
- 2009-09-24 AR ARP090103683A patent/AR073677A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2009296820A1 (en) | 2010-04-01 |
| WO2010036613A8 (en) | 2010-11-18 |
| TWI393709B (zh) | 2013-04-21 |
| EP3924343A1 (en) | 2021-12-22 |
| CA2737694A1 (en) | 2010-04-01 |
| JP2012503661A (ja) | 2012-02-09 |
| MX2011003239A (es) | 2011-04-28 |
| US8394969B2 (en) | 2013-03-12 |
| AU2009296820B2 (en) | 2014-03-20 |
| AR073677A1 (es) | 2010-11-24 |
| US20100081643A1 (en) | 2010-04-01 |
| CA2737694C (en) | 2013-07-02 |
| CN102361857A (zh) | 2012-02-22 |
| TW201016672A (en) | 2010-05-01 |
| CN102361857B (zh) | 2015-09-16 |
| WO2010036613A1 (en) | 2010-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5764064B2 (ja) | 抗糖尿病薬として有用な新規な環状ベンゾイミダゾール誘導体 | |
| JP5575137B2 (ja) | 抗糖尿病剤として有用な新規な環状ベンゾイミダゾール誘導体 | |
| JP5557845B2 (ja) | 糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体 | |
| US8563746B2 (en) | Cyclic benzimidazole derivatives useful as anti-diabetic agents | |
| US8895596B2 (en) | Cyclic benzimidazole derivatives useful as anti-diabetic agents | |
| US8796258B2 (en) | Cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20120302 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120809 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120809 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20130223 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131224 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20131226 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140320 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20141007 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141217 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150602 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150612 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5764064 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313115 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |